Cibus, Inc. Class A Common Stock (CBUS) is a publicly traded Healthcare sector company. As of May 21, 2026, CBUS trades at $1.38 with a market cap of $97.70M and a P/E ratio of -0.13. CBUS moved +8.46% today. Year to date, CBUS is -29.70%; over the trailing twelve months it is -49.73%. Its 52-week range spans $1.09 to $6.10. Analyst consensus is buy with an average price target of $14.67. Rallies surfaces CBUS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cibus Raises $37M but Logs $21.2M Loss, Rice Launch Delayed to 2029: Cibus raised $37 million in Q1 through two public offerings and reported a net loss of $21.2 million on $1.7 million revenue. The company established seven Rice Seed Company partnerships across LATAM and the U.S. and delayed its U.S. herbicide-tolerant rice launch from 2028 to 2029.
| Metric | Value |
|---|---|
| Price | $1.38 |
| Market Cap | $97.70M |
| P/E Ratio | -0.13 |
| EPS | $-10.83 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.10 |
| 52-Week Low | $1.09 |
| Volume | 2 |
| Avg Volume | 0 |
| Revenue (TTM) | $4.26M |
| Net Income | $-282.71M |
| Gross Margin | 0.00% |
3 analysts cover CBUS: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.67.